Open AccessGenotype resistance profiles in patients failing an NNRTI‐containing regimen, and modifications after stopping NNRTI therapy
Author(s) -
QuirosRoldan Eugenia,
Airoldi Monica,
Moretti Francesca,
Fausti Caterina,
Pan Angelo,
Casari Salvatore,
Torti Carlo,
Castelli Francesco,
Carosi Giampiero
Publication year - 2002
Publication title -
journal of clinical laboratory analysis
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.536
H-Index - 50
eISSN - 1098-2825
pISSN - 0887-8013
DOI - 10.1002/jcla.10022
Subject(s) - efavirenz , nevirapine , virology , regimen , reverse transcriptase inhibitor , protease inhibitor (pharmacology) , reverse transcriptase , medicine , drug resistance , nucleoside reverse transcriptase inhibitor , resistance mutation , salvage therapy , genotype , antiretroviral therapy , human immunodeficiency virus (hiv) , biology , viral load , chemotherapy , genetics , rna , gene
Resistance to non‐nucleoside reverse transcriptase inhibitors (NNRTIs) develops quickly and independently if they are used in combination with NRTIs or protease inhibitors (PIs) as rescue therapy, mainly due to the low genetic barrier of this class of drugs. In this study we examined clinical, therapeutic, and virologic characteristics in 88 patients with mutations conferring resistance to NNRTIs, and in 11 patients 1 year after stopping NNRTI therapy. Between patients administered Nevirapine (NVP) and those taking Efavirenz (EFV), no statistical differences were found in CD4 cell count, HIV viral load, time on NNRTI therapy, or number of PIs administered previously. A slow decline in the detectability of mutations encoding NNRTI resistance was found. J. Clin. Lab. Anal. 16:76–78, 2002. © 2002 Wiley‐Liss, Inc.